Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach by Velez, N. (Nieves) et al.
Predicting Relapsing-Remitting Dynamics in Multiple
Sclerosis Using Discrete Distribution Models: A
Population Approach
Nieves Velez de Mendizabal1,2*, Matthew M. Hutmacher3, In˜aki F. Troconiz4, Joaquı´n Gon˜i5,
Pablo Villoslada6, Francesca Bagnato7,8, Robert R. Bies1,2
1 Indiana University School of Medicine; Indianapolis, Indiana, United States of America, 2 Indiana Clinical and Translational Sciences Institute (CTSI), Indianapolis, Indiana,
United States of America, 3Ann Arbor Pharmacometrics Group (A2PG), Ann Arbor, Michigan, United States of America, 4Department of Pharmacy and Pharmaceutical
Technology, School of Pharmacy, University of Navarra, Pamplona, Spain, 5Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana,
United States of America, 6Center for Neuroimmunology, Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Barcelona, Spain,
7Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, United States of America, 8Department of Neurology,
University of Maryland, Baltimore, Maryland, United States of America
Abstract
Background: Relapsing-remitting dynamics are a hallmark of autoimmune diseases such as Multiple Sclerosis (MS). A clinical
relapse in MS reflects an acute focal inflammatory event in the central nervous system that affects signal conduction by
damaging myelinated axons. Those events are evident in T1-weighted post-contrast magnetic resonance imaging (MRI) as
contrast enhancing lesions (CEL). CEL dynamics are considered unpredictable and are characterized by high intra- and inter-
patient variability. Here, a population approach (nonlinear mixed-effects models) was applied to analyse of CEL progression,
aiming to propose a model that adequately captures CEL dynamics.
Methods and Findings: We explored several discrete distribution models to CEL counts observed in nine MS patients
undergoing a monthly MRI for 48 months. All patients were enrolled in the study free of immunosuppressive drugs, except
for intravenous methylprednisolone or oral prednisone taper for a clinical relapse. Analyses were performed with the
nonlinear mixed-effect modelling software NONMEM 7.2. Although several models were able to adequately characterize the
observed CEL dynamics, the negative binomial distribution model had the best predictive ability. Significant improvements
in fitting were observed when the CEL counts from previous months were incorporated to predict the current month’s CEL
count. The predictive capacity of the model was validated using a second cohort of fourteen patients who underwent
monthly MRIs during 6-months. This analysis also identified and quantified the effect of steroids for the relapse treatment.
Conclusions: The model was able to characterize the observed relapsing-remitting CEL dynamic and to quantify the inter-
patient variability. Moreover, the nature of the effect of steroid treatment suggested that this therapy helps resolve older
CELs yet does not affect newly appearing active lesions in that month. This model could be used for design of future
longitudinal studies and clinical trials, as well as for the evaluation of new therapies.
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Introduction
Multiple sclerosis (MS) is a prototypic autoimmune disease that
affects the central (CNS) with a relapsing-remitting (RR) disease
progression [1]. Clinical relapses in MS, acute symptoms that
appear in episodic periods, are considered to be the reflection of
focal inflammatory events in the white matter that disrupts neural
conduction by damaging axons [2]. Clinical relapses are used to
categorize different forms of the disease, i.e. RR versus progressive
MS, as a marker to define the disease’s disease progression and to
measure the success of new therapies [2].
Magnetic Resonance Image (MRI) is a useful tool for
understanding and following the disease progression in patients
with MS [3–5]. The focal inflammatory events of the CNS that
accompany a clinical MS relapse are evident on MRI recordings
as contrast enhancing lesions (CELs) on T1-weighted images [6].
This kind of MRIs shows CELs four to ten times more frequently
compared with clinically defined relapses [7]. That is, clinical
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relapses may not occur even if a CEL is observed. Therefore,
CELs are more informative biomarker for disease progression than
the Expanded Disability Status Score (EDSS). The natural history
of a CEL is highly variable both within and between patients
(Figure 1). In MS, CELs and associated clinical relapses generally
last for a month with spontaneous partial or full recovery
afterwards. The CEL distribution over time has not been
associated with any specific pattern or cause to date [2,8].
However, in one third of cases, relapses are preceded by either a
stressful events and/or infections [9,10].
The number of CELs measured every month is a discrete
response variable that can take only non- negative integer values
(Figure 1). Modelling such count data has been applied to different
processes including anticonvulsant responses [11,12], incontinence
[13], neonatal apnea [14] and epileptic seizures [15,16]. Com-
monly the Poisson distribution (PS) model is used to describe the
data. The mean counts in an arbitrary time interval for the PS
model can be denoted as l which can be influenced by several
factors as drug effect, covariates (sex, weight, age…), disease
progression, etc. The PS model has two restrictions: the mean (l) is
equal to the variance of the data and the numbers of events
occurring in non-overlapping intervals of time are assumed
independent. This is a significant challenge as many counting
outcomes show (i) bigger or smaller variability than that predicted
by the Poisson model, a phenomenon called over-dispersion or
under-dispersion respectively and (ii) lack of independence in the
counts observed in previous intervals. Therefore, discrete distri-
bution models other that the Poisson should be explored to
evaluate this heterogeneity along with the evaluation of Markovian
elements to adjust for correlation in counts between intervals.
Identification of models that better characterize the distribution of
CELs is relevant for two reasons. First, it provides a predictive
framework for the relapsing-remitting dynamic observed in
patients with MS. Second, it can serve to inform the design of
longitudinal studies of this disease. While several count distribu-
tions have been proposed to model this type of data, the negative
binomial (NB) distribution has been consistently found to provide
one of the better fits to the data [17–20]. Although the NB has
already demonstrated a very good fitting with this kind of count
data, it might be the case that the election of a smaller interval
period for the MRI acquisitions had produced a different analysis
outcome. The best scanning interval and analysis for this outcome
is not clear since monthly scans generally provided more
prediction power but they are more expensive [21]. In this study
we analysed the distribution of CELs developed by nine MS
patients whom underwent monthly MRI for 48 months. Here we
used the unique high resolution of this dataset for the exploration
of other distributions adding other factors that might effect
changes in the disease dynamic. Concretely, Markovian effects on
the model parameters have been explored and quantified. In
addition, how corticosteroids affect the lesions counts was also
included during the model exploration and development. The
short interval between MRI acquisitions (one month) shows an
adequate time resolution to capture the relapsing-remitting
dynamics of this disease.
Figure 1. Number of contrast-enhancing lesions (CELs). CEL counts are represented with circles and dashed lines (left Y axis). Some patients
were treated with intravenous methylprednisolone at 1 g/day for 3–5 days, or oral prednisone taper for clinical relapses (arrows). Changes in the
EDSS are plotted on the right Y axis (red line).
doi:10.1371/journal.pone.0073361.g001
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Results
Several models were evaluated, resulting in sixteen key
structural models based on seven different probability distribu-
tions. Based on the number of model parameters, the objective
function (table 1) and the precision of the parameters the best
fitting distribution was the negative binomial (equation 10)
overcoming the other explored distributions like (Poisson model,
Poisson model with mixture distribution, Zero-Inflated and
Generalized Poisson models and the Zero-Inflated Negative
Binomial model). When the variance and the mean of number
of CELs were calculated from the raw data by subject, the
variances were greater in magnitude than the means for all but 1
patient (Figure 2). A statistically significant difference in the
objective function value (OFV) was observed when a first order
Markov parameter hPDV, which modified the mean counts (l)
parameter based on the counts observed from the previous MRI,
was incorporated (NB MAK2 model, equation 4). When a second
order Markov parameter hPPDV was included (NB nested MAK2
model, equation 5) relating the current mean count to the observed
count two months prior, the statistical difference also significant,
but the magnitude of the second order effect was less
(hPDV.hPPDV ). The same decreasing pattern, hPDV.hPPDV.
hPPPDV, was observed although the fit improvement was not
significant when a third order Markov parameter was also
included (NB nested nested MAK2 model, equation 6). Therefore,
the best model was the negative binomial model (equation 10) with
first and second order Markov parameters (equation 5): NB nested
MAK2 model.
Table 1 shows the parameter differences among models as well
as the corresponding objective function values. Selected model (NB
nested MAK2) estimates are listed in table 2 with the corresponding
relative standard error (RSE %). The fixed effects parameters were
estimated with adequate precision, however the RSE associated
with the random effects was high as we expected (N= 9 subjects).
All parameters and random effects variables for the sixteen models
are listed in Table 1 with the objective function values.
The goodness of fit of the models was evaluated using
simulation-based methods (see methods). Figure 3 shows the
results for visual numerical predictive checks (VNPC) of several
dynamic descriptors: (i) probability of having of 0, 1, 2, 3, 4, 5, 6, 7
and .8 CELs (Figure 3A), (ii) maximum and mean elapsed time
without lesions during the four years (Figure 3 B) and (iii)
cumulative number of CELs per year (Figure 3C). We compared
the prediction performance of selected models explored in this
manuscript: Poisson model (PS), Poisson model with first order
Markov factor (PMAK2) and Negative Binomial model with first
and second order Markov factors (NB nested MAK2). In general the
NB nested MAK2 performed better for most of the descriptors. None
of the models adequately capture the stiff dynamic along the
percentiles for the probability of having no CELs.
In order to evaluate better the predictive capacity of the NB
nested MAK2, the prediction intervals for the dynamic descriptors
previously defined were calculated (Figure 4). The model captures
the observed percentiles for a majority of the descriptors
reasonably well. The CEL count distributions for the raw and
simulated data for the selected model were also compared for
model evaluation (Figure 5). Figure 6 shows the prediction interval
for variance versus mean of number of CELs with the patient data.
The model is able to capture the relationship between the mean
number of CELs and the variance of those counts. Based on these
visual model evaluations it was concluded that the NB nested MAK2
model describes the observed data and better than other explored
distributions.
The model was also validated with data from a second cohort.
Model simulations for the maximum, median and mean of the
number of CELs during 6 months were compared with fourteen
patients with RRMS whom underwent monthly MRIs during a 6-
month pre-therapy phase (Figure S1). The model captured
reasonably well the median and mean although slightly under-
predicted (Figure 7A). The maximum number of active lesion was
clearly under-predicted (Figure 7A). The predicted interval for
variance versus mean of number of CELs for a 6 month time
window was slightly under-predicted for smaller means (Figure 7B).
The disease activity in the group of patients used for the model
validation was higher than the group used for the model building;
for example, the number of CELs per patient per month in
average was 4.08 and 3.26 for model validation and model
building respectively.
During the study, six patients were treated with immunomod-
ulatory or immunosuppressive drugs (intravenous methylprednis-
olone at 1 g/day for 3–5 days or oral prednisone) for alleviation of
clinical relapses. The months in which these patients received
steroids are indicated in figure 1. A parameter for the effect of
steroids was evaluated on: l0, OVDP, hPDV and hPPDV. Although
the use of immunosuppressive drugs occurred infrequently, a
steroid administration effect on the CEL events was quantifiable.
A statistically significant improvement in OFV was observed when
the effect was included on hPDV instead in l0. This relationship
was further evaluated utilizing a randomization test approach (see
methods); figure 8 shows 99.3% of the randomized schemes
resulted in a higher OFV, highlighting the impact of the steroid
effect (p-value = 0.007). Table 3 shows the estimates with the
corresponding relative standard error (RSE %) for the selected
model with the steroid covariate effect. Comparing values, the
parameter values for l0, hPDV and hPPDV changed slightly to:
21.80%; 3.80%; and 2.75% respectively. The OVPD parameter
dropped 14.86%, indicating that part of the over dispersion
observed in the data might be due to the immunomodulatory
treatment. The parameter hPDV, is diminished 66.44% when the
patient was treated with immunosuppressive drugs for that month
(hPPDV_S). This result suggests that the use of steroids contributes
to the inflammatory resolution of persistent CELs but does not
affect the new CELs generated that month. Other implications of
this result are indicated in the discussion section. The steroid
covariate inclusion into the model, that is a within subject effect,
did not explain the ISV associated to l0 and hPDV. All fixed effects
parameters were estimated with adequate precision except hPPDV.
The RSE associated with the random effects were similar to the
selected model with no steroid effect. The steroid effect was also
evaluated for the following month that the patient received the
treatment; however no significant effect was identified.
Discussion
The disease progression of CEL dynamics is highly variable
both within and between patients. In this study we identified a
discrete distribution model from a pool of candidate models that
best described the distribution of CELs in these patients. Although
several models were able to describe the data reasonably well, the
negative binomial resulted in the best fit. The identified over-
dispersion indicates the presence of greater intra-patient variability
(variance) in the number of CELs during a period of time (48
month, 48 points) than what is expected based on the mean.
All of the models had significant improvements in fit when the
information about what happened in the previous months was
incorporated (i.e., Markovian elements). Nevertheless the impor-
tance of previous observations diminishes with increasing time
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from the observation. This may be attributable to the fact that the
CEL counts noted every month were the total number of CELs,
and thus, older lesions observed in previous months might persist
in the current one. Working under this hypothesis, the results
suggest that such persistent CELs may last up to 2 months. In
other words, this indicates that although the clinical relapse
(symptoms that appear in episodic acute periods) usually last less
than a month, the active inflammatory event might persist for a
longer time.
It is well known that the focal inflammatory events in the CNS
that accompany a clinical multiple sclerosis relapse show complex
dynamics. There is the potential for a great deal of insight to be
generated if mechanistic elements, e.g. balance between effector
and regulatory T cell, were incorporated to these kinds of
probabilistic models [22]. The idea would be to identify latent
variables that explain variations in the mean counts (l).
Unfortunately, with data available, we were not able to develop
a more mechanistic model.
The selected model (called NB nested MAK2) describes the
observed data well and better than other explored distributions
(Figure 3, Figure 4). Although all the parameters were estimated
with adequate precision, the RSE associated with the random
effects were high. Therefore, the estimated values for the ISV of
the parameters l0 and, hPDV are not well determined. However, as
shown in figure 4, the prediction intervals simulated from the
model for all descriptors of CEL response captured the observed
response percentiles well.
The model was externally validated with data from a second
cohort. Model predictions were adequate for the median and
mean numbers of events, but the maximum number of events was
under-predicted. The predicted interval for variance versus mean
of number of CELs was also slightly under-predicted for smaller
means. These under-predictions are probably due to the disease
being more active in the data set used for the validation than in the
group of patients used for the model building (the average number
of CELs per patient per month was 4.08 in the validation set and
Table 1. Summary of the discrete-distribution models evaluated.
MODELS PARAMETERS 22LL(D model)
PS hl vl 2068.725
0.744 0.442
PMAK1 hl1 hl2 vl1 2001.0 (267.55 PS)
0.932 2.76 0.542
PMAK2 hl0 hPDV vl0 vPDV 1725.51 (2343.212 PS)
1.18 0.418 0.562 0.187
nested PMAK2 hl0 hPDV hPPDV vl0 vPPDV 1713.88 (211.63 PMAK2)
1.03 0.388 0.124 0.501 0.164
nested nested PMAK2 hl0 hPDV hPPDV hPPPDV vl0 vPDV 1711.49 (214.02 PMAK2)
0.956 0.396 0.0974 0.0595 0.487 0.143
PMIX hl1 hl2 hPM vl1 vl2 1867.23 (+141.72 PMAK2 )
2.72 1.81 0.413 0.529 1.89
ZIP hl1 hP0 vl1 2036.40 (+310.49 PMAK2)
2.4 0.0375 0.91
GP hl hdisp vl 1808.41 (+82.9 PMAK2)
1.53 0.393 0.663
GP_MAK2 hl0 hdisp hPDV vl0 vPDV 1665.50 (260.01 PMAK2)
0.902 0.371 0.232 0.451 0.0932
GP_nested_MAK2 hl0 hdisp hPDV hPPDV vl0 vPDV 1654.96 (270.55 PMAK2)
0.742 0.347 0.121 0.23 0.365 0.058
NB hl hOVDP vl vOVDP 1758.92 (+33.41 PMAK2)
2.32 0.254 0.898 0.829
ZINB hl hOVDP hP0 vl vOVDP 1758.63 (+33.12 PMAK2)
2.32 0.254 0 0.898 0.829
NB_MAK2 hl hOVDP hPDV vl vPDV 1642.85 (282.66 PMAK2)
1.11 0.161 0.462 0.524 0.155
NB_nested MAK2 hl hOVDP hPDV hPPDV vl vPDV 1634.36 (28.49 NB_MAK2)
0.94 0.155 0.43 0.141 0.44 0.121
NB_nested nested MAK2 hl hOVDP hPDV hPPDV hPPPDV vl vPDV 1630.77 (23.59 NB_nested MAK2)
0.817 0.157 0.448 0.104 0.0955 0.401 0.0849
NB_nested MAK2 steroids hl hOVDP hPDV hPDV_S hPPDV vl vPDV 1624.048 (210.312 NB_nested MAK2)
0.923 0.132 0.447 0.15 0.145 0.438 0.127
Values between parentheses are the decreases/increases in the objective function value relative to a specified reference model.
doi:10.1371/journal.pone.0073361.t001
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3.26 in the model building set). In theory, the level of over-
dispersion of the 6 months simulated data should be identical to
that use to simulate 48 months of data. However, when comparing
both simulated data sets (6 and 48 months), we realized that this is
not the case. The lower overdispersion found in 6 months
simulated data is an effect of the number of months (or number of
observations) within the subject. As a matter of fact, the same
phenomenon also occurs if we select any 6 consecutive months of
the 48 months in the observed data. Therefore, higher over-
dispersion is expected for both simulated and observed data when
larger time windows are used for the calculation of the mean and
corresponding variance of the number of active lesions.
During the course of the study, six of the nine patients were
treated with corticosteroids for clinical relapses. We explored a
steroid effect on all model parameters: l0, OVDP, hPDV and
hPPDV. A significant improvement in fit was found when the effect
was included on hPDV instead of l0. This result suggests that the
use of steroids contributes to the inflammatory resolution of
persistent CELs (older CELs) but that it is not affecting to the
newer CELs generated in the month after administration.
Specifically, the model suggests that the use of steroids would
help to resolve approximately the 66% of the persistent CELs.
This result was further evaluated utilizing a randomization test
strategy. One thousand randomized ensembles of the dose event
architecture (see methods) were simulated to test this. Figure 8
shows the histogram of the OF values calculated (22LL) from the
simulations. 99.3% of the randomized schemes resulted in a higher
OF, highlighting the statistical relevance of steroid effect
(p,0.007). The steroid drug effect was evaluated not only for
the month in which the patient received steroids, but also for the
following month. Although a decrease for l0 when patients
received steroids in the previous month was identified, this result
was not significant. These results reflect the utility of this modelling
approach for drug effect evaluation, providing a quantitative
framework that can support the informed design of future
longitudinal studies and other clinical trials.
The best probabilistic model, fitting the distribution of CELs
developed by nine MS patients undergoing monthly MRI
evaluations over 48 months, was developed. The information that
can be extracted from this kind of count data depends on the
resolution with which data are collected as well as the coincidence
of the measurement paradigm with the CEL cycle. Other
approach/methodologies have been applied with relative similar
purposes [17–21,23–24]. Although in general the number of
patients analysed in those studies was larger; the recording timings
for the MRIs was not of sufficient resolution for capturing the
CELs dynamic. The short interval between MRI acquisitions (one
month) provides an appealing time resolution to capture the
relapsing-remitting complex dynamics of the CELs. In this data
analysis, an additional step was taken by applying the nonlinear
mixed effect modelling approach. This provides a quantitative
analysis of the data allowing the incorporation and quantification
of both fixed and random effects. This approach takes into
account the information from all patients simultaneously, defining
both the population tendency for each parameter and the inter-
patient variability in that parameter. This methodology has been
widely applied and evaluated in research fields such as pharmaco-
metrics. It is an approach that is especially well suited for the
analysis of repeated measurements. The selected model was
comprehensively evaluated (OFV comparisons, goodness of fit
plots, visual/numerical predictive checks, parameter precision…)
and externally validated using data from a second cohort.
Materials and Methods
Patients and MRI Scans
The study was performed at the National Institutes of Health in
Bethesda, MD, USA. The Intramural Research Board of the
National Institute of Neurological Disorders and Stroke approved
the study. Informed written consent was obtained from each
patient. The MRIs were performed on a 1.5-T magnet (General
Electric Medical Systems, Milwaukee, Wisconsin) using a standard
head coil as previously described. At each monthly MRI, the total
number of contrast-enhancing lesions (CELs) on T1-weighted
post-contrast scans was identified by experienced radiologists
(Figure 1). Clinical and imaging details about this cohort are
described in detail elsewhere [25]. Nine patients with MS were
sequentially enrolled. Patients were enrolled in the study if they
had never been treated with immunomodulatory or immunosup-
pressive drugs, except for intravenous methylprednisolone at 1 g/
day for 3–5 days, or oral prednisone taper for a clinical relapse. In
addition, patients were required to be able to complete monthly
MRI scans and to have been steroid-free for at least 1 month at
study entry. After a complete neurological examination, including
rating disability using the Expanded Disability Status Score
(EDSS) and initial MRI scan at baseline, patients were
Table 2. NB nested MAK2 model parameters.
Parameters Estimate RSE(%) ISV (CV%) RSE(%)
l0 0.940 24.14 66.33 60.90
OVDP 0.155 22.19
hPDV 0.430 23.72 34.78 71.57
hPPDV 0.141 30.99
RSE (%) relative standard error.
doi:10.1371/journal.pone.0073361.t002
Figure 2. Variance versus mean of number of CELs obtained
from the raw data. Each observation represents one patient and is
represented by dots. Solid black line represents the identity line.
Dashed red line is the linear data fit.
doi:10.1371/journal.pone.0073361.g002
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subsequently examined and imaged monthly. The number of total
CELs in each month was calculated as the sum of all the CELs
that were enhancing at that month for the last time. Thus, each
CEL considered for the analysis was counted only once.
Data Analysis
Data were analysed employing the population approach using
the Laplacian integral approximation method implemented in the
software NONMEM version VII (Icon Development Solutions,
Hanover, Maryland).
Models for Count Data
Sixteen models based on seven different probability distributions
were explored: (i) Poisson model, (ii) Poisson model with Markov
elements, (iii) Poisson model with mixture distribution, (iv) Zero-
Inflated Poisson model, (v) Generalized Poisson model, (vi)
Negative Binomial model and (vii) Zero-Inflated Negative
Binomial model.
i. Poisson model (PS). The Poisson distribution is used to model
the number of events occurring within a given time interval.
The PS model is expressed by the probability P (likelihood)
that the random variable Y is equal to the number of counts n
(equation 1). The parameter lambda l represents the mean
number of counts in a given time period and is the unique
parameter of this model. The use of a PS model implies the
assumption of equi-dispersion, meaning equality between the
mean and the variance of the data (equation 2). Another
important assumption of this model is that the number of
Figure 3. Visual Numerical Predictive Check (VNPC). Different dynamic descriptors were calculated for the observed data (black solid line) and
the simulated data from the different selected models (dashed lines). Those descriptors were evaluated at different percentiles from 5th to 95th with
an increasing step of 5.
doi:10.1371/journal.pone.0073361.g003
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counts (l) occurring in non-overlapping intervals of time is
independent.
P Yi~nð Þ~ e
{l|ln
n!
, n~ 0,1,2,3,:::½  ð1Þ
E Yið Þ~Var Yið Þ~l ð2Þ
ii. Poisson model with Markov elements (PMAK). The Markov-
ian element provides for the dependence of events across
Figure 4. Predicted Interval of Visual Numerical Predictive Check. Different dynamic descriptors were calculated for the observed data (black
solid line) and simulated data NB nested MAK2 model. The 95% predicted interval is represented red area. Dashed red represented the simulated
median. Those descriptors were evaluated at different percentiles from 10th to 90th with an increasing step of 5.
doi:10.1371/journal.pone.0073361.g004
Figure 5. Probability distribution for CEL. Observed data (A) versus the probability distribution of simulated data (B) generated by NB nested
MAK2 model.
doi:10.1371/journal.pone.0073361.g005
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time-points. Markov elements were explored for Poisson
model in two different ways: PMAK1 and PMAK2. Stating
that an observation is conditional on the previous one, and
not the one before, is permitted by the inclusion of a first order
Markovian component. Higher orders were also incorporated.
a. PMAK1 model (equation 3). A binary covariate PDV1 was
included in the data file taking the value 1 or 0 depending on
whether there was at least one CEL or not at the previous
month
P Yi~nð Þ~
e{l1|ln1
n!
, forPDV1~0
e{l2|ln2
n!
, forPDV1~1
8>><
>: ð3Þ
b. PMAK2. The covariate PDV was created and incorporated
taking the value of the previous dependent variable. In this
case, the parameter l is modified by the PDV term (equation
4). Higher orders were also explored: second (equation 5) and
third (equation 6) order Markovian component, called nested
PMAK2 and nested nested PMAK2 respectively.
Figure 6. Predicted Interval for variance versus mean of number of CELs. Variance and mean of number of CELs in each patient (observed –
simulated) were calculated and represented in natural logarithmic scale. Solid line in black corresponds to the identity line. Blue dots are the
observations. Blue dashed lines correspond to the 5th and 95th quartiles of simulated data and solid blue line corresponds to the median of simulated
data. Black solid line is the identity line.
doi:10.1371/journal.pone.0073361.g006
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l~l0zPDV|hPDV ð4Þ
l~l0zPDV|hPDVzPPDV|hPPDV ð5Þ
l~l0zPDV|hPDVzPPDV|hPPDVzPPPDV|hPPPDV ð6Þ
iii. The Poisson model utilizing a mixture distribution for
individual observations (PMIX) (equation 7) incorporates an
additional parameter, the mixture probability (MP) for an
observation to belong to one of the two mixture distribution
(characterized by two different ls) within an individual [26]:
P Yi~nð Þ~MP| e
{l1|ln1
n!
z 1{MPð Þ| e
{l2|ln2
n!
) ð7Þ
iv. Zero-Inflated Poisson model (ZIP) is a mixture model adapted
for data presenting an excess of zero values and therefore
needing an adaptation of the distribution that is otherwise
extremely skewed. ZIP is a special case of PMIX where l1 is
equal to 0. It is composed of two equations depending on
whether the random variable is a zero or a greater value and
they include the probability P0 of the observation being zero
(equation 8). If P0 is equal to zero, the ZIP model reduces to
the PS model. The mean monthly CEL count and the
variance will be given by the following expressions [(1 – P0)
6l] and [(1 – P0)6l6 (1+ P06l)], respectively.
P Yi~nð Þ~
e{l|ln
n!
| 1{P0ð ÞzP0, for n~0
e{l|ln
n!
| 1{P0ð Þ, for nw0
8><
>: ð8Þ
v. Generalized Poisson model (GP) (equation 9) possesses the
twin property of over dispersion and under dispersion [27].
This is contained in the dispersion parameter d that can be
positive or negative within the adaptive range [max (21, 2l/
4), 1]. First (equation 5) and second (equation 6) order Markov
elements were explored for this distribution models affecting
to the l parameter, called GP PMAK2 and GP nested
PMAK2 respectively.
P Yi~nð Þ~ e
{l{nd|l| lzndð Þn{1
n!
ð9Þ
vi. Negative Binomial model (NB) is used when there is over
dispersion due to latent heterogeneity (equation 10). The NB
model is a mixture of the Poisson distribution when the mean
follows a Gamma distribution [28] and is a function of l and a
parameter which accounts for the degree of over dispersion
called here OVDP. The mean is still l, but the variance
becomes l6(1-OVDP6l). As OVDP approaches zero the
NB model approaches the PS model. OVPD is restricted to be
positive. First (equation 4), second (equation 5) and third
(equation 6) order Markov elements were explored for this
distribution models affecting to the l parameter, called NB
PMAK2, NB nested PMAK2 and NB nested nested PMAK2
respectively.
P Yi~nð Þ~
C nz 1
OVDP
 
n!|C 1
OVDP
 
" #
|
1
1zOVDP|l
  1
OVDP
|
l
1
OVPD
zl
 !n ð10Þ
vii. Zero-Inflated Negative Binomial model (ZINB). Equation 11
corresponds to the zero-inflated negative binomial. The
parameters P0 and OVDP have the same meaning as in the
ZIP model. The ZINB model reduces to the ZIP, NB or PS
model when P0, OVDP or both approaches zero, respectively
Figure 7. Model validation. A. Three descriptors were compared: (i) maximum, (ii) median and (iii) mean of the number of CELs during the 6
months. Green dots represented the observed data; dotted lines are the observed median; black dashed lines are the predicted median and grey
areas the 95% PI by the model. B. Variance versus mean for a 6 time window. Green dots are observations. Green dashed lines correspond to the 5th
and 95th percentiles of simulated data and the solid green line corresponds to the median of simulated data. Black solid line is the identity line.
doi:10.1371/journal.pone.0073361.g007
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Once the basic structure of the model was identified, the effect
of the steroid treatments on the model parameters was
evaluated. This was done for every model parameter, i.e., l0,
OVDP, hPDV and hPPDV. The drug effect was evaluated not
only for the month in which the patient received steroids, but
also for the following month to evaluate longer-term or
delayed effects.
Model Development and Selection Criteria
The minimum value of the objective function (OFV) provided
by NONMEM, which corresponds approximately to 226log(li-
kelihood) [22LL], served as a criteria for model comparison
during the model development process. A decrease in 22LL of
6.63 points for one additional parameter, was regarded as a
significant model improvement corresponding to p-value of
0.01 for nested models. The Akaike information criteria (AIC),
calculated as AIC=22LL+26NP, where NP is the number of
parameter in the model, was used for selection among non-nested
models [29]. The choice of the final model was based also on the
OFV value, the precision of parameter estimates, and the results
from model predictive performance where raw data and data
obtained from model simulations were compared.
Model Evaluation
Models were evaluated in more detail as follows: (i) Visual
Numerical Predictive Checks (VNPC). One thousand individuals
were simulated using the selected models and their model
parameter estimates. For the observed data and each simulated
dataset the following descriptors were calculated: probability of
having of 0, 1, 2, 3, 4, 5, 6, 7 and .8 CELs, maximum and mean
elapsed time without lesions during the four years and number of
cumulative CELs per year. For every descriptor, the increasing
percentiles from 5th to 95th were calculated. The results for the raw
and simulated data with the different models were plotted where X
axis represent the different percentiles (Figure 3). (ii) Predicted
interval of VNPC. One thousand studies with 9 individuals per
study were simulated using the selected model. The same dynamic
descriptors that were described for the VNPC were used here. For
every descriptor, the increasing percentiles from 10th to 90th were
Figure 8. Analysis of the significance of the steroid effect by randomizing the dose events. One thousand new data files were generated
by randomizing the doses event architecture while preserving the total number of dose events and the patient observations. The histogram shows
the distribution of the OF values obtained using the selected model with the steroid effect when drug administrations were randomly generated. The
OF value of the selected model with no steroid effect is marked in green. The OF value of the selected model with the covariate steroid effect, using
the real dose moments is highlighted in red.
doi:10.1371/journal.pone.0073361.g008
(11)
Table 3. NB nested MAK2 with steroid effects model
parameters.
Parameters Estimate RSE(%) ISV (CV%) RSE(%)
l0 0.923 26.54 66.18 59.58
OVDP 0.132 25.37
hPDV 0.447 21.40 35.63 73.85
hPDV_S 0.145 32.06
hPPDV 0.150 48.00
RSE (%) relative standard error.
doi:10.1371/journal.pone.0073361.t003
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calculated. The 95% prediction interval by model was plotted with
the data (Figure 4). (iii) Probability CEL distribution; observed
data was compared to the probability distribution of simulated
data generated by the selected model (Figure 5). (iv) Predicted
interval for variance versus mean of number of CELs; one
thousand simulated individuals with the selected model were
generated. The individual mean CELs counts and the individual
variance for every patient were computed from the raw data. The
same computations were then made for each simulated individual
and year; for a total of 1000. The results were divided into 20
intervals for the mean of CELs, with each interval containing 50
simulated subjects. For each interval, variances were binned, and
the median and 5th–95th percentiles were calculated. Finally, the
overall median and percentiles were represented graphically
together with those corresponding to the raw data (Figure 6).
Model Validation
Fourteen patients with relapsing-remitting multiple sclerosis
underwent monthly MRIs during a 6-month pre-therapy phase.
None of these patients were treated with any immunosuppressive
therapy before the first scan. On each MRI, the total number of
CELs was noted (Figure S1). This open-label study was performed
at the National Institutes of Health, Bethesda, Maryland, with
approval from the institutional review board [30]. Three
descriptors were used for model validation (Figure 7A): (i)
maximum number of CELs, (ii) median of the CEL counts and
(iii) mean of the number of CELs collected during the 6 months
pre-therapy phase. Moreover, the predicted interval for variance
versus mean number of CELs for a 6 time window by the selected
model was compared with the same values from the data set
(Figure 7B).
Randomization of the Steroid Dose Administrations
A randomization test to calibrate the false positive rate for the
evaluation of the steroid effect was conducted. Specifically, one
thousand new data files were generated by randomizing the dose
event architecture while preserving the total number of dose events
and the patient observations.
Supporting Information
Figure S1 Cohort for model validation. CEL counts are
represented with circles and dashed lines (left Y axis).
(TIF)
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